Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer (Q24604601)

24

0 references

Alberto Bardelli

26

0 references

Andrea Sartore-Bianchi

16

0 references

Salvatore Siena

23

0 references

Sandra Misale

Sandra Misale

1

0 references

Silvio Marco Veronese

Silvio Veronese

14

0 references

Emanuele Valtorta

Emanuele Valtorta

7

0 references

Giulia Siravegna

Giulia Siravegna

10

0 references

Enzo Medico

Enzo Medico

21

0 references

Marcello Gambacorta

17

Marcello Gambacorta

0 references

Sebastijan Hobor

3

Sebastijan Hobor

0 references

Michela Buscarino

9

Michela Buscarino

0 references

Elisa Scala

4

Elisa Scala

0 references

author name string

Rona Yaeger

2

0 references

Manickam Janakiraman

5

0 references

David Liska

6

0 references

Roberta Schiavo

8

0 references

Katia Bencardino

11

0 references

Andrea Cercek

12

0 references

Chin-Tung Chen

13

0 references

Carlo Zanon

15

0 references

Margherita Gallicchio

18

0 references

Efsevia Vakiani

19

0 references

Valentina Boscaro

20

0 references

Martin Weiser

22

0 references

David Solit

describes a project that uses

25

0 references

language of work or name

English

0 references

publication date

28 June 2012

0 references

published in

Nature

0 references

volume

486

0 references

issue

7404

0 references

page(s)

532-6

0 references

DiFi

0 references

LIM1215

0 references

LIM1215 KRAS (G12A/+)

0 references

LIM1215 KRAS (G12C/+)

0 references

LIM1215 KRAS (G12D/+)

0 references

LIM1215 KRAS (G12R/+)

0 references

LIM1215 KRAS (G12S/+)

0 references

LIM1215 KRAS (G12V/+)

0 references

LIM1215 KRAS (G13D/+)

0 references

cites work

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3927413

Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3927413

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3927413

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3927413

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3927413

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3927413

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3927413

Circulating mutant DNA to assess tumor dynamics

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3927413

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3927413

Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3927413

EGFR antagonists in cancer treatment

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3927413

Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3927413

Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3927413

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3927413

Nuclear EGFR contributes to acquired resistance to cetuximab

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3927413

Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3927413

Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3927413

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3927413

A colon cancer cell line (LIM1215) derived from a patient with inherited nonpolyposis colorectal cancer.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3927413

Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3927413

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3927413

28 November 2018

Identifiers

DOI

10.1038/NATURE11156

1 reference

Dimensions Publication ID

229157

1024120060

0 references

229157

1 reference

1 reference

1 reference